Methods for diagnosing, treating, and monitoring the treatment of invasive aspergillosis (IA) are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having IA.

Velvet disease infestation is detected using affinity reagents that are cross-reactive with one or more A. ocellatum or P. pillulare antigens. The analysis may be performed shipboard, dockside, in an aquaculture or aquarium setting, otherwise in situ at the point of sample collection or elsewhere. The results may be used to monitor health and disease of captured or cultured fish species or the safety of water to be introduced into an aquaculture facility.

Embodiments of the present technology include a method for testing a blood sample for sepsis. The method may include receiving a blood sample from an individual. The method may also include executing an instruction to analyze the blood sample for sepsis. In addition, the method may include measuring values of a set of characteristics in the blood sample. The set of characteristics being determined prior to measuring the values. The method may further include analyzing the values of the set of characteristics to produce a representation of a suspicion of sepsis. In addition, the method may include displaying the representation. Embodiments also include systems for testing blood sample for sepsis.

The present invention provides methods of treating inflammation associated with infection, and methods of preventing or reducing the severity of sepsis caused by inflammation associated with infection, in an individual comprising, consisting essentially of or consisting of the steps of administering a therapeutically effective amount of idronoxil, or derivative, pharmaceutically acceptable salt, ester, amide, polymorph and/or prodrug thereof to the individual, wherein the individual is diagnosed with, or suspected of having, early stage organ damage caused by inflammation associated with infection.

The present invention relates to a method of diagnosing a human sepsis. The present invention further relates to a kit for diagnosing a human sepsis. The present invention also relates to a point-of-care device for performing a method of diagnosing a human sepsis. The present invention also relates to a use of a kit and/or a point-of-care device for a method of diagnosing a human sepsis. The present invention also relates to the use of a kit and/or a point-of-care device for a method of diagnosing a human sepsis. The method comprises stimulating a platelet-specific (hem-)ITAM receptor by adding a (hem-)ITAM receptor agonistic agent to a blood sample of a patient, wherein said agonistic agent comprises CRP-XL and/or convulxin, and measuring a platelet function level.

Described herein are methods that use blood biomarkers to identify an increased risk of multiple independent infection episodes (MIIE) before clinical signs of infection appear. Thus, provided herein are methods for detecting or predicting risk of developing multiple independent infection episodes (MIIE) in a subject who has experienced blunt trauma.

Described herein are compositions that comprise one or more Babesia microti antigens, one or more Babesia microti nucleic acid molecules, or one or more anti-Babesia microti antibodies and uses thereof in methods for the prophylaxis of babesiosis, the treatment of babesiosis and the monitoring of individuals undergoing prophylactic or therapeutic administration of the compositions of the invention.

The present invention relates to a biomarker composition for diagnosing Johne's disease using the measurement of alpha-2-macrogolublin (A2M) and use thereof.

Since the biomarker of the present invention can provide improved sensitivity to subclinical infections by revealing differences in the expressions of host proteins in the serum of MAP-infected subjects during various stages of JD progression, it can be effectively used to eradicate JD from a population of subjects. In particular, since the biomarker of the present invention is detected using the ELISA method, it is possible to diagnose Johne's disease more efficiently than when other methods such as mass spectrometry are used, and it can be directly applied in the field. In addition, it is possible to provide a more excellent diagnostic effect than the existing ELISA kits for diagnosing Johne's disease that are commercially available.

A new monoclonal antibody targeting the VP-1 protein of the capsid of the BK polyomavirus, fragments thereof, and uses of same for detecting infection with the BK polyomavirus. The monoclonal antibody is capable of recognizing at least all serotypes Ia, Ib2, II, III and IV of the VP-1 protein of the BK polyomavirus.

A process is provided for isolating and analyzing microorganisms contained in a sample by collecting a determined volume in a sample, the determined volume representing all or part of this sample, likely to contain at least one microorganism. The collected volume is then split up into a plurality of compartments having a culture medium, the volume of each compartment being smaller than 10 μL, each compartment being isolated from the other compartments and having no interface with the ambient atmosphere. At least one microorganism is incubated in the compartments for determined durations, and compartments are detected that contain at least one microorganism. The incubation may be extended after detecting compartments so that at least one microorganism having a defined quantity can be detected, and then the content of the detected compartments can be recovered. Finally, at least one functional parameter relative to a microorganism in the compartments is determined.